Opinion: China’s New Supply‑Chain Rules Could Disrupt Western Biopharma
A Stat News opinion piece cites a recent paper showing China’s rise to the world’s leading trial volume and warns that its newly tightened supply‑chain regulations may pose major logistical and regulatory challenges for Western pharmaceutical companies.
Реклама: Article Inline